Scientific Advisory Board
L. Edward Ellinwood, Ph.D., M.D.
Dr. Ellinwood is a nationally-recognized clinical pharmacologist with extensive expertise in the field of lung cancer research. A native of Colorado Springs, Colorado, Ellinwood obtained a Ph.D. in pharmacology and toxicology from the distinguished University of Chicago in 1951 and graduated from the University of Colorado School of Medicine in 1957.
Following his internship at the U.S. Naval Hospital in Oceanside, California, Ellinwood became an instructor of toxicology and pharmacology at the University of Chicago and later served as a staff pharmacologist at the world-renowned Los Alamos Scientific Laboratory in New Mexico.
After a six-year tenure as an industrial physician with Union Carbide Nuclear Corporation, Ellinwood spent 13 years as a private practitioner in Grand Junction, Colorado. In 1977, he became the director of the family residence program at St. Mary's Hospital and Medical Center in Grand Junction, for which he has served as the director emeritus since 1986.
Ellinwood is currently the principal investigator for clinical drug research trials at St. Mary's and is a co-investigator for the early detection and treatment of lung cancer in uranium miners at the Los Alamos National Laboratories.
Janet Mercer-Smith, Ph.D., is a distinguished molecular chemist with an extensive research and teaching background, She currently serves as a Group Leader in the Polymers and Coatings Group at Los Alamos National Laboratory (LANL). Dr. Mercer-Smith graduated Magna Cum Laude from Hardin-Simmons University, Abilene, Texas with a degree in Chemistry, and received her Ph.D. in chemistry from University of North Carolina, Chapel Hill, North Carolina.
Dr. Mercer-Smith served as both a section leader and a principal investigator for the Radiolabeling Research Program, Nuclear and Radiochemistry Group at Los Alamos National Laboratory. She was appointed an Adjunct Clinical Associate professor at the University of New Mexico College of Pharmacy, and has served as Assistant Professor and Principal Investigator for The Rockefeller University, New York, New York.
Dr. Mercer-Smith has published nearly 30 papers on a wide variety of molecular chemistry topics with particular emphasis in porphyrin chemistry and radiolabeling. She won an award from the American Chemical Society for her paper “New Approaches to Cancer Therapy.” In addition, she has been the principal presenter at nearly a dozen conferences, including two presentations at the 200th National Meeting of the American Chemical Society, Washington, D.C., on the topics of “Radiometallating Antibodies and Biologically Active Peptides” and “ A Synthetic Porphyrin Compound with High Affinity for Lung Cancer Cells and Inflamed Lymphatic Tissue.” She was also the Moderator for the International Symposium on New Trends in Radiopharmaceutical Synthesis, Quality and Regulatory Control at this meeting.
Dr. Mercer-Smith is a member of the American Chemical Society, Environmental, Inorganic, Organic and Nuclear Chemistry Divisions; the American society for Photobiology, the BioPhysical Society and the Society of Nuclear Medicine, Radiopharmaceutical Division, of which she was elected Vice-President for the New Mexico, Rocky Mountain Chapter.
Buck A. Rhodes, Ph.D., M.D.
With over 30 years of expertise in the field of radiopharmaceutical research, Dr. Rhodes brings a wealth of diverse experience, clinical analysis and business acumen to Biomoda. A graduate of prestigious Johns Hopkins University with a Ph.D. in radiological science, Rhodes most recently served as president of RhoMed Incorporated, a biotechnology company specializing in radiopharmaceuticals. Rhodes now serves as a consultant to the company and is president of Buck Rhodes Biomedical Consulting in Albuquerque.
A former professor of radiology at Johns Hopkins University and the University of New Mexico, Rhodes has acted as a consultant to Abbott Laboratories, The 3M Company, the International Atomic Energy Commission and other domestic and international organizations. In addition to chairing or co-chairing five international meetings on nuclear medicine, he has published or co-published over 160 scientific papers, seven textbooks and eight audio-visual programs, and has served as the principal investigator for grants and contracts totaling over $5,000,000.
An honorary diplomate of the American Board of Science in Nuclear Medicine, Rhodes has prepared and submitted several Investigational New Drug (IND) applications with the U.S. Food and Drug Administration, and has personally been issued 12 medical product-related U.S. patents, with 12 patents pending.
Go Back to the Biomoda Inc. Main Menu